Table 2. Characteristics of patients with CIHT.

Variable	Patients with CIHT requiring treatment (n=8)
Median age (years)	54 (range 44–69)
Site of primary tumour	Colon: 5; rectum: 2; unknown: 1
Chemotherapy regimen	Capecitabine/oxaliplatin combination: 8 patients Capecitabine alone: 0 (total screened population receiving capecitabine alone: 56 (26%))
Treatment intent	Adjuvant: 5 Palliative: 3
History of diabetes	2 Patients, both non-insulin-dependent (total number screened diabetic patients=30)
Known history of dyslipidaemia or any lipid-lowering therapy	Dyslipidaemia: 1 patient receiving atorvastatin therapy before chemotherapy, but no previous fibrate therapy Lipids never previously tested: 5 Lipids previously tested but normal: 2
Previous history of ischaemic heart disease	None
Previous history of hypertension	1 Patient on anti-hypertensive therapy
Previous line of capecitabine therapy	4 Patients
Renal function	All patients with documented creatinine clearance of >60 ml min−1
Alcohol consumption	Never consume: 3 Moderate consumption: 3 Above safe recommended limit: 2
Median body surface area (m2)	1.84 (range 1.64–2.28)

Abbreviation: CIHT=capecitabine-induced hypertriglyceridaemia.